drugset / Trial / NCT00318409
Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM
Phase 2
Completed
30 enrolled
San Francisco Department of Public Health
National Institute on Drug Abuse (NIDA) · collabPublic Health Foundation Enterprises, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. No studies have tested the feasibility and acceptability of conducting pharmacologic interventions to reduce meth use and meth-associated sexual risk behavior among MSM. The purpose of this pilot study is to determine the feasibility enrolling and retaining meth-dependent MSM into a pharmacologic study of bupropion vs. placebo and measuring the tolerability of and adherence to medication among these participants.
Timeline
- Start
- 2006-09
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupropion | Small molecule | 300 mg | — |